Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.44 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10409229 | 0.83 | ALDH1A1 (0.44) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL4893786 | 0.80 | ALDH1A1 (0.46) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL2576152 | 0.79 | ALDH1A1 (0.41) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL11789811 | 0.78 | ALDH1A1 (0.44) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| Hydrochloric Acid SCHEMBL11789817 | 0.78 | ALDH1A1 (0.44) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL4425287 | 0.78 | LMNA (0.46) | CHRM5CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL9847009 | 0.78 | THRB (0.52) | ALDH1A1TSHRHTT | |
| SCHEMBL13357700 | 0.78 | ALDH1A1 (0.40) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL2466611 | 0.76 | ALDH1A1 (0.43) | ALDH1A1CHRM5CHRM1CHRM3PGR | |
| SCHEMBL10409275 | 0.76 | ALDH1A1 (0.47) | ALDH1A1CHRM5CHRM1CHRM3PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111918881-B | Novel photocrosslinkable alginic acid derivative | 持田制药株式会社 | 2022-08-12 | — | — | CN | disclosed |
| US-9024014-B2 | Phosphorus-containing compounds and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024014-B2 | Phosphorus-containing compounds and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120178714-A1 | Phosphorus-containing Compounds & Uses Thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8058426-B2 | Phosphorus-containing compounds and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100197907-A1 | Phosphorus-containing compounds & uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7709020-B2 | Rapamaycin derivatives used as fungicides, anticarcinogenic agents, immunosuppressants or as coatings on drug eluting stents to prevent restenosis | ARIAD PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070190106-A1 | Phosphorus-containing compounds & uses thereof | MEDINOL LTD. (IL) | 2007-08-16 | — | — | US | disclosed |
| US-7186826-B2 | Phosphorus-containing compounds and uses thereof | ARIAD GENE THERAPEUTICS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-4056571-A | Process for the preparation of tertiary phosphine oxides | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197907-A1 | Phosphorus-containing compounds & uses thereof | NR5A2, NR2E3, VDR | ALDH1A1 4692/4885CHRM5 25/4885CHRM1 394/4885 |
| US-20070190106-A1 | Phosphorus-containing compounds & uses thereof | NR5A2, NR2E3, VDR | ALDH1A1 4692/4885CHRM5 25/4885CHRM1 394/4885 |
| US-20120178714-A1 | Phosphorus-containing Compounds & Uses Thereof | ALPP, ALPI, PHOSPHO1 | ALDH1A1 2663/4885CHRM5 4298/4885CHRM1 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.